Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Cambridge Nutritional Sciences PLC (CNSL)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
3.25 -0.05    -1.52%
11:35:59 - Closed. Currency in GBP ( Disclaimer )
Type:  Equity
Market:  United Kingdom
ISIN:  GB00B1VCP282 
SEDOL:  B1VCP28
  • Volume: 152,847
  • Bid/Ask: 2.90 / 3.40
  • Day's Range: 3.20 - 3.30
Cambridge Nutritional Sciences 3.25 -0.05 -1.52%

LON:CNSL Financials

 
A brief overview of the LON:CNSL financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of Omega over time.

Cambridge Nutritional Sciences plc reported earnings results for the half year ended September 30, 2023. For the half year, the company reported sales was GBP 4.93 million compared to GBP 3.43 million a year ago. Net loss was GBP 0.698 million compared to GBP 2.09 million a year ago. Basic loss per share from continuing operations was GBP 0.003 compared to GBP 0.004 a year ago. Diluted loss per share from continuing operations was GBP 0.003 compared to GBP 0.004 a year ago. Basic loss per share was GBP 0.003 compared to GBP 0.009 a year ago. Diluted loss per share was GBP 0.003 compared to GBP 0.009 a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

CNSL Income Statement

Gross margin TTM 52.9%
Operating margin TTM -25.11%
Net Profit margin TTM -27.32%
Return on Investment TTM -19.27%
 Total Revenue  Net Income
Period Ending: Mar 31, 2023 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Total Revenue 2.06 1.72 1.72
Gross Profit 0.846 0.926 0.926
Operating Income -1.03 -0.325 -0.325
Net Income -0.886 -1.04 -1.04

CNSL Balance Sheet

Quick Ratio MRQ 3.55
Current Ratio MRQ 4.12
LT Debt to Equity MRQ -
Total Debt to Equity MRQ 2.3%
 Total Assets  Total Liabilities
Period Ending: Mar 31, 2023 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Total Assets 14.4 17.13 17.13 17.84
Total Liabilities 4.45 5.33 5.33 6.02
Total Equity 9.95 11.8 11.8 11.82

CNSL Cash Flow Statement

Cash Flow/Share TTM -0.01
Revenue/Share TTM 0.04
Operating Cash Flow  -35.26%
 Cash  Net Change in Cash
Period Ending: Mar 31, 2023 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities -0.684 -0.892 -0.892
Cash From Investing Activities 1.97 0.62 0.62
Cash From Financing Activities -0.082 0.825 0.825
Net Change in Cash 1.2 0.554 0.554
* In Millions of GBP (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

CNSL Comments

Write your thoughts about Cambridge Nutritional Sciences PLC
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Aisha AbuShhewa
Aisha AbuShhewa May 10, 2021 3:08AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I think that tweet over the weekend was purposely tweeted to drop the SP so the directors could buy more prior to the big announcement.
sumit singh
sumit singh May 10, 2021 3:08AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Do you have any news on omega?
John Johnson
John Johnson Feb 11, 2021 3:52AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Omega Diagnostics confirms deal with UK to manufacture Covid lateral flow tests.Everything falling into place here.
John Johnson
John Johnson Feb 09, 2021 7:27AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Getting really exciting now, endorsement as a key UK government manufacturer in the FT. Government orders in the pipeline. Huge upside.
Crypto Ash
Crypto Ash Nov 14, 2020 6:55PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This SP will easily reach £2 this year. Strong fundamentals, orders are around the corner. MHRA Approval imminent. US, India and China orders coming soon.
John Johnson
John Johnson Sep 09, 2020 5:41AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
In four months, this company will be manufacturing 2m+ C-19 tests / week with an avg profit of £1 / test. It will generate more profit more than its current mcap. It has a huge diversification of high quality tests in partnership with Mologic and a part of the UK-RTC set up by the uk gov. The company also has food intolerance and CD4 divisions as well as developing LFT for Cryptococcus and TB -LAM, underpinning the company's value post covid. Price target of 250p (£475m mcap)
Scott seefeldt
Scott seefeldt Sep 09, 2020 5:41AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Or in four months this company could still be sat waiting for orders, capacity is one thing... but IP and orders is what counts. On the covid front they have neither.
Jonny Tr
Jonny Tr May 08, 2020 2:03AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Biolidics Enters Distribution Agreement With Mediproud Co for COVID19 test Kits
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email